Loading...
•
Mar 31, 2023
Harmony Biosciences Q1 2023 Earnings Report
Harmony Biosciences reported strong first-quarter performance with increased WAKIX net revenue and advancements in clinical development programs.
Key Takeaways
Harmony Biosciences reported a strong first quarter in 2023, marked by a 40% year-over-year increase in WAKIX net revenue, reaching $119.1 million. The company also saw growth in GAAP net income, which rose to $29.5 million, and made progress in its clinical development programs.
WAKIX net revenue increased by approximately 40% year-over-year, reaching $119.1 million.
The average number of patients on WAKIX increased by approximately 1,200 year-over-year, totaling approximately 5,100 patients.
GAAP net income increased to $29.5 million, or $0.48 earnings per diluted share.
Non-GAAP adjusted net income was $40.1 million, or $0.66 earnings per diluted share.
Revenue by Segment
Forward Guidance
Harmony Biosciences anticipates topline data in the fourth quarter of 2023 in Phase 3 Idiopathic Hypersomnia (“IH”) INTUNE Study.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...